Ocular Surface Articles & Analysis: Older
9 news found
François Blondel: ‘We work in three specific areas: degradation of the cartilage and the synovial fluid of joints, in order to combat problems with arthritis; skin ageing, which can result in the appearance of wrinkles; drying of the ocular surface, which is commonly known as ‘dry eye syndrome’. ...
—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. ...
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. ...
If left untreated, MGD can present serious consequences, including ocular surface damage, changes in tear film stability, inflammation, pain, chronic dry eye, and other symptoms that can greatly impair a person’s daily life and vision. ...
Osmolarity testing enables clinicians to detect visually significant ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery. ...
BySOFIE
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. ...
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership ...
Parma and Modena, 16 June 2020 – Chiesi Farmaceutici, international research-focussed group (Chiesi Group), and Holostem Terapie Avanzate, top Italian biotech company entirely dedicated to the development, production, registration and distribution of medicinal products for advanced therapies, announce the signing of a contract for the transfer of the business branch of Holoclar®, an ...
Citizens will be able to visit the research laboratories of Holostem and the Regenerative Medicine Center “Stefano Ferrari” and discover the path that leads from basic research to the development of two advanced therapies: cell therapy for the reconstruction of the ocular surface and gene therapy for the epidermolysis bullosa or butterfly children ...